Certain types of life science research involving “high consequence pathogens and toxins” would be subject to new review and risk mitigation procedures which might include classification of the research or termination of the funding, according to a U.S. government policy issued yesterday by the National Institutes of Health.
The policy applies to research involving 15 specified biological agents and toxins which “pose the greatest risks of deliberate misuse with most significant potential for mass casualties or devastating effects to the economy, critical infrastructure or public confidence.”
Research that increases the lethality or transmissibility of the agent or toxin, or otherwise enhances its harmful consequences, will be subject to the new review procedures.
Based on the outcome of the review, a risk mitigation plan may be developed. If less restrictive measures were deemed inadequate, the new policy would allow for national security classification of the research or termination of government funding.
See “United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern,” March 29, 2012.
See also “U.S. Requires New Dual-Use Biological Research Reviews” by David Malakoff, Science Insider, March 29.
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.